Atopic Dermatitis

Below is a list of our atopic dermatitis studies that are currently enrolling.

A Study to Investigate the Efficacy and Safety of ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis

  • Population: Patients aged two to five years old
  • Study Condition: Mild to moderate eczema
  • Study Design: this is a four-week placebo-controlled study.  Participants will be randomly chosen to either receive ARQ-151 or a vehicle cream.  The vehicle cream or placebo is a “dummy” cream that is made from the same base product that is used to make ARQ-151, but it does not contain any active study drug.  Participants will apply the ARQ-151 or vehicle once every day for one month.
  • Compensation may be provided

 

Topical Ruxolitinib Evaluation in Atopic Dermatitis

  • Population: Patients aged two to eleven years old
  • Study Condition: Mild to moderate atopic dermatitis
  • Study Design:  The purpose of this research study is to determine if an investigational cream, ruxolitinib cream (0.75% and 1.5% strengths), is safe and effective to treat Atopic Dermatitis. In this study, ruxolitinib cream will be compared to a “vehicle cream.”  The vehicle cream looks like the ruxolitinib cream but contains no ruxolitinib. This study can last up to 55 weeks. For the first 8 weeks participants will be randomly assigned to receive either the ruxolitinib cream or vehicle cream. For the following 44 weeks participants will receive the ruxolitinib cream.
  • Compensation will be provided

 

Please contact Dr. Carolina Porter for more information regarding ongoing atopic dermatitis studies. 

 

Email: portecar@musc.edu

Phone: (843) 876-0110